Dabi Yohann, Bendifallah Sofiane, Suisse Stéphane, Haury Julie, Touboul Cyril, Puchar Anne, Favier Amélia, Daraï Emile
Sorbonne University - Department of Obstetrics and Reproductive Medicine, Hôpital Tenon, 4 rue de la Chine, 75020 Paris; Clinical Research Group (GRC) Paris 6: Centre Expert Endométriose (C3E), Sorbonne University (GRC6 C3E SU); INSERM UMR_S_938, Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, Paris 75020, France.
Sorbonne University - Department of Obstetrics and Reproductive Medicine, Hôpital Tenon, 4 rue de la Chine, 75020 Paris; Clinical Research Group (GRC) Paris 6: Centre Expert Endométriose (C3E), Sorbonne University (GRC6 C3E SU); INSERM UMR_S_938, Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, Paris 75020, France.
Transl Oncol. 2022 Nov;25:101512. doi: 10.1016/j.tranon.2022.101512. Epub 2022 Aug 9.
Breast cancer in women is the second most common cancer and the fifth leading cause of cancer death worldwide. Although earlier diagnosis and detection of breast cancer has resulted in lower mortality rates, further advances in prevention, detection, and treatment are needed to improve outcomes and survival for women with breast cancer as well as to offer a personalized therapeutic approach. It is now well-established that non-coding RNAs (ncRNAs) represent 98% of the transcriptome but in-depth knowledge about their involvement in the regulation of gene expression is lacking. A growing body of research indicates that ncRNAs are essential for tumorigenesis by regulating the expression of tumour-related genes. In this review, we focus on their implication in breast cancer genesis but also report the latest knowledge of their theragnostic and therapeutic role. We highlight the need for accurate quantification of circulating ncRNAs which is determinant to develop reliable biomarkers. Further studies are mandatory to finally enter the era of personalized medicine for women with breast cancer.
女性乳腺癌是全球第二常见的癌症，也是癌症死亡的第五大主要原因。尽管早期诊断和检测乳腺癌已使死亡率降低，但仍需要在预防、检测和治疗方面取得进一步进展，以改善乳腺癌女性的治疗效果和生存率，并提供个性化的治疗方法。目前已明确，非编码RNA（ncRNA）占转录组的98%，但对其参与基因表达调控的深入了解仍很缺乏。越来越多的研究表明，ncRNAs通过调节肿瘤相关基因的表达对肿瘤发生至关重要。在本综述中，我们重点关注它们在乳腺癌发生中的作用，同时也报告它们在诊断治疗和治疗方面的最新知识。我们强调准确量化循环ncRNAs的必要性，这对于开发可靠的生物标志物至关重要。必须进行进一步研究，以便最终进入乳腺癌女性的个性化医疗时代。
